Clinical trial Recruiting at 1 site Observational Ages 0 Hours to 6 Hours

POP-Score: A simple, non-invasive test to see if newborns might have early infection

Official title: The Peripheral(-Muscle) Oxygenation and Perfusion Score (POPScore) a New Non-invasive Tool to Predict Elevations in C-reactive Protein Levels in Neonates - a Prospective Phase II Observational Study

Run by Medical University of Graz · NCT07109856 · Data updated 2026-11-12

This study tests whether the POP-Score, a non-invasive measure using NIRS and routine vitals, can predict elevated CRP in term and near-term neonates within 48 hours of birth.

Quick facts

Study typeObservational
Ages0 Hours to 6 Hours
SexAll
Enrollment93 (estimated)
SponsorMedical University of Graz
Academic / other
Locations1 site (Graz, Styria)
StatusRecruiting
StartedNovember 27, 2025
Main results expectedMarch 1, 2028
Study endsMay 1, 2028
Registry record updatedMay 14, 2026
Trial IDNCT07109856 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Term or moderate-to-late preterm neonates (birth weight ≥2000 g) with respiratory distress and risk factors for infection, whose guardians provide consent within 6 hours of birth.

Probably not a fit

Neonates without infection risk factors or whose CRP would not elevate despite other illness may not benefit from POP-Score findings.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-center observational study at the Medical University of Graz. It evaluates whether the Peripheral(-muscle) Oxygenation and Perfusion Score (POP-Score), which combines peripheral muscle oxygenation from NIRS with heart rate, oxygen saturation, systolic blood pressure, and skin fat thickness, can predict CRP elevations (≥20 mg/L) within 48 hours after birth. Measurements include multi-site NIRS data (cerebral, peripheral muscle, intestinal, and flank) collected in neonates with respiratory distress and risk factors for infection. Eligible infants are term or moderate-to-late preterm with birth weight ≥2000 g and parental consent obtained within the first 6 hours of life. The study aims to establish an optimal POP-Score cut-off within 6 hours post-birth for early infection screening.

Why it matters

Potential benefit: If successful, this approach could enable earlier identification of infection or inflammation in newborns using a non-invasive score.

How similar studies have gone: Prior pilot data suggested high sensitivity and good specificity for predicting elevated CRP with the POP-Score, supporting further validation in a larger cohort.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* birth weight ≥ 2000 grams
* Signs of respiratory distress at time-point of inclusion (tachypnoea \>60/min, grunting, intercostal/subcostal/jugular retractions, nasal flaring, supplemental oxygen or respiratory support)
* Decision to conduct full life support
* Written informed consent obtained within the first 6 hours after birth, before inclusion in the study
* Age \< 6 hours

Exclusion Criteria:

* No decision to conduct full life support
* No written informed consent
* Birth weight \< 2000 grams
* Age \> 6 hours
* Severe congenital malformations,
* Umbilical cord artery pH \<7.20

Where it's running

  • Medical University of Graz, Division of Neonatology
    Graz, Styria, Austria
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.